Acute migraine treatments in patients above age 65
Abstract
Background: Migraine remains a prevalent and disabling condition in older adults, yet there are limited data guiding acute treatment in patients over the age of 65 years. This population is often underrepresented in clinical trials and there are special considerations to take with management in this population including age-related pharmacokinetic changes, comorbidities, and increased risk of medication-related adverse effects.
Objective: In this narrative review, we aim to highlight the current acute treatments for migraine and considerations that should be taken when choosing medications in older adults, including assessing vascular risk factors, polypharmacy, declining kidney function, delayed gastric emptying, and impaired liver metabolism.
Methods: This is a narrative review on the current literature and evidence for the use of acute medications in patients with migraine who are 65 years old or older. The authors queried both PubMed and Google Scholar for relevant publications in February-March 2025.
Results: The authors provide a breakdown of acute medication treatment options and include special considerations by class. The classes discussed include non-steroidal anti-inflammatory drugs, acetaminophen, triptans, ergotamines, gepants, ditans, neuromodulation, and nerve blocks.
Conclusion: Ultimately, effective and safe acute migraine management in patients over age 65 years requires applying the best available evidence, understanding knowledge gaps, and engaging in…
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.